Characterization of the Stem Cell Fraction in Pancreatobiliary Carcinomas: The Notch Signaling Pathway as a Potential Therapeutic Target — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Characterization of the Stem Cell Fraction in Pancreatobiliary Carcinomas: The Notch Signaling Pathway as a Potential Therapeutic Target
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
,
Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
1 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
2 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
3 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
4 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
5 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
6 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
7 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
8 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
9 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
10 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
11 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
12 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
Pancreatic adenocarcinoma (PDAC) and extrahepatic cholangiocarcinoma (ECC) are highly lethal malignancies with limited treatment options. Both a small subpopulation of cancer stem cells (CSC) and the deregulation of the notch pathway have been considered potential sources of tumor formation. In this study, flow cytometry (FCM) was conducted to identify the CSC population and Notch-associated proteins in ECC and PDAC cell lines. Additionally, the treatment effect of Gemcitabine and the specific notch-inhibitor DAPT on ECC and PDAC cell lines was evaluated. Our results show that the amount of SP cells in ECC cell lines is significantly higher than in PDAC cell lines, and that SP-ECC cells show a higher sensitivity to therapy. In conclusion, inhibition of Notch signaling with DAPT may be of therapeutic value in ECC, but seems to show no effect on more aggressive PDAC. As it could be essential for the improvement in outcomes of the ECC patients, other trials are needed to determine the role of further Notch components.
Bailey, J.M., DelGiorno, K.E. and Crawford, H.C. (2014) The Secret Origins and Surprising Fates of Pancreas Tumors. Carcinogenesis, 35, 1436-1440. https://doi.org/10.1093/carcin/bgu056
Razumilava, N. and Gores, G.J. (2013) Classification, Diagnosis, and Management of Cholangiocarcinoma. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 11, 13-21.
Seufferlein, T., Porzner, M., Heinemann, V., Tannapfel, A., Stuschke, M. and Uhl, W. (2014) Ductal Pancreatic Adenocarcinoma. Deutsches Arzteblatt International, 111, 396-402. https://doi.org/10.3238/arztebl.2014.0396
Schmuck, R.B., de Carvalho-Fischer, C.V., Neumann, C., Pratschke, J. and Bahra, M. (2016) Distal Bile Duct Carcinomas and Pancreatic Ductal Adenocarcinomas: Postulating a Common Tumor Entity. Cancer Medicine, 5, 88-99. https://doi.org/10.1002/cam4.566
Deshpande, V., Konstantinidis, I.T., Castillo, C.F., Hezel, A.F., Haigis, K.M., Ting, D.T., et al. (2016) Intra-Pancreatic Distal Bile Duct Carcinoma Is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 20, 953-959.
Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et al. (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. The New England Journal of Medicine, 364, 1817-1825. https://doi.org/10.1056/NEJMoa1011923
Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. https://doi.org/10.1056/NEJMoa1304369
Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., et al. (2013) Cancer Stem Cells in Solid Tumors: An Overview and New Approaches for Their Isolation and Characterization. FASEB Journal, 27, 13-24. https://doi.org/10.1096/fj.12-218222
Wang, X., Liu, Q., Hou, B., Zhang, W., Yan, M., Jia, H., et al. (2013) Concomitant Targeting of Multiple Key Transcription Factors Effectively Disrupts Cancer Stem Cells Enriched in Side Population of Human Pancreatic Cancer Cells. PLoS ONE, 8, e73942.
Bolos, V., Grego-Bessa, J. and de la Pompa, J.L. (2007) Notch Signaling in Development and Cancer. Endocrine Reviews, 28, 339-363. https://doi.org/10.1210/er.2006-0046
Vaccaro, V., Melisi, D., Bria, E., Cuppone, F., Ciuffreda, L., Pino, M.S., et al. (2011) Emerging Pathways and Future Targets for the Molecular Therapy of Pancreatic Cancer. Expert Opinion on Therapeutic Targets, 15, 1183-1196. https://doi.org/10.1517/14728222.2011.607438
13 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
14 Charité—Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitatzu Berlin, and Berlin Institute of Health, Institute of Surgery, Augustenburger Platz 1, Berlin, Germany
Nakanuma, Y. (2010) A Novel Approach to Biliary Tract Pathology Based on Similarities to Pancreatic Counterparts: Is the Biliary Tract an Incomplete Pancreas? Pathology International, 60, 419-429. https://doi.org/10.1111/j.1440-1827.2010.02543.x
Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J.T., Gellert, K., Ridwelski, K., et al. (2013) Adjuvant Chemotherapy with Gemcitabine and Long-Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA, 310, 1473-1481. https://doi.org/10.1001/jama.2013.279201
Sinn, M.B.M., Denecke, T., Travis, S., Pelzer, U. and Riess, H. (2016) Perioperative Treatment Options in Resectable Pancreatic Cancer—How to Improve Long-Term Survival. World Journal of Gastrointestinal Oncology, 8, 248-257. https://doi.org/10.4251/wjgo.v8.i3.248
Plentz, R., Park, J.S., Rhim, A.D., Abravanel, D., Hezel, A.F., Sharma, S.V., et al. (2009) Inhibition of Gamma-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 136, 1741-1749e6.
Mullendore, M.E., Koorstra, J.B., Li, Y.M., Offerhaus, G.J., Fan, X., Henderson, C.M., et al. (2009) Ligand-Dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer. Clinical Cancer Research, 15, 2291-2301. https://doi.org/10.1158/1078-0432.CCR-08-2004
Kang, M., Jiang, B., Xu, B., Lu, W., Guo, Q., Xie, Q., et al. (2013) Delta like Ligand 4 Induces Impaired Chemo-Drug Delivery and Enhanced Chemoresistance in Pancreatic Cancer. Cancer Letters, 330, 11-21. https://doi.org/10.1016/j.canlet.2012.11.015
Mazur, P.K., Einwachter, H., Lee, M., Sipos, B., Nakhai, H., Rad, R., et al. (2010) Notch2 Is Required for Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Ductal Adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 107, 13438-13443. https://doi.org/10.1073/pnas.1002423107
Riedlinger, D., Bahra, M., Boas-Knoop, S., Lippert, S., Bradtmoller, M., Guse, K., et al. (2014) Hedgehog Pathway as a Potential Treatment Target in Human Cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 21, 607-615. https://doi.org/10.1002/jhbp.107
Hao, K., Tian, X.D., Qin, C.F., Xie, X.H. and Yang, Y.M. (2013) Hedgehog Signaling Pathway Regulates Human Pancreatic Cancer Cell Proliferation and Metastasis. Oncology Reports, 29, 1124-1132. https://doi.org/10.3892/or.2012.2210
El Khatib, M., Bozko, P., Palagani, V., Malek, N.P., Wilkens, L. and Plentz, R.R. (2013) Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 in Vivo. PLoS ONE, 8, e77433.
Lee, J.Y., Song, S.Y. and Park, J.Y. (2014) Notch Pathway Activation Is Associated with Pancreatic Cancer Treatment Failure. Pancreatology, 14, 48-53. https://doi.org/10.1016/j.pan.2013.11.011
Ostroukhova, M., Qi, Z., Oriss, T.B., Dixon-McCarthy, B., Ray, P. and Ray, A. (2006) Treg-Mediated Immunosuppression Involves Activation of the Notch-HES1 Axis by Membrane-Bound TGF-Beta. The Journal of Clinical Investigation, 116, 996-1004. https://doi.org/10.1172/JCI26490
Kared, H., Adle-Biassette, H., Fois, E., Masson, A., Bach, J.F., Chatenoud, L., et al. (2006) Jagged2-Expressing Hematopoietic Progenitors Promote Regulatory T Cell Expansion in the Periphery through Notch Signaling. Immunity, 25, 823-834. https://doi.org/10.1016/j.immuni.2006.09.008
Cook, N., Frese, K.K., Bapiro, T.E., Jacobetz, M.A., Gopinathan, A., Miller, J.L., et al. (2012) Gamma Secretase Inhibition Promotes Hypoxic Necrosis in Mouse Pancreatic Ductal Adenocarcinoma. The Journal of Experimental Medicine, 209, 437-444. https://doi.org/10.1084/jem.20111923
Yabuuchi, S., Pai, S.G., Campbell, N.R., de Wilde, R.F., De Oliveira, E., Korangath, P., et al. (2013) Notch Signaling Pathway Targeted Therapy Suppresses Tumor Progression and Metastatic Spread in Pancreatic Cancer. Cancer Letters, 335, 41-51. https://doi.org/10.1016/j.canlet.2013.01.054
Krop, I., Demuth, T., Guthrie, T., Wen, P.Y., Mason, W.P., Chinnaiyan, P., et al. (2012) Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients with Advanced Solid Tumors. Journal of Clinical Oncology, 30, 2307-2313.
Tolcher, A.W., Messersmith, W.A., Mikulski, S.M., Papadopoulos, K.P., Kwak, E.L., Gibbon, D.G., et al. (2012) Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. Journal of Clinical Oncology, 30, 2348-2353. https://doi.org/10.1200/JCO.2011.36.8282
Messersmith, W.A., Shapiro, G.I., Cleary, J.M., Jimeno, A., Dasari, A., Huang, B., et al. (2015) A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral Gamma-Secretase Inhibitor PF-03084014. Clinical Cancer Research, 21, 60-67. https://doi.org/10.1158/1078-0432.CCR-14-0607
Goodell, M.A. (2005) Stem Cell Identification and Sorting Using the Hoechst 33342 Side Population (SP). Current Protocols in Cytometry, Chapter 9, Unit 9, 18.
Herzenberg, J., Moore, W.A., Herzenberg, L.A. and Parks, D.R. (2006) Interpreting Flow Cytometry Data: A Guide for the Perplexed. Nature Immunology, 7, 681-685.